What hepatitis B virus (HBV) DNA level indicates the need for antiviral therapy?

There is no single “threshold” hepatitis B virus (HBV) DNA level that universally triggers antiviral therapy. Clinical decisions are based on a comprehensive assessment—not just viral load—incorporating alanine aminotransferase (ALT) levels, liver fibrosis stage (assessed via non-invasive tests like FibroScan® or biopsy), presence of cirrhosis, age, family history of hepatocellular carcinoma (HCC), and HBV genotype and serologic markers (e.g., HBeAg status). For example, in HBeAg-positive chronic hepatitis B, treatment is generally recommended if HBV DNA exceeds 20,000 IU/mL *and* ALT is persistently elevated (>2× upper limit of normal) with evidence of active inflammation or fibrosis. In contrast, HBeAg-negative disease often warrants treatment at lower thresholds—typically HBV DNA >2,000 IU/mL—when accompanied by elevated ALT and histologic activity. Notably, all patients with compensated or decompensated cirrhosis should receive antiviral therapy regardless of ALT or viral load, due to high risk of disease progression and HCC. Guidelines from major societies—including the American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), and Asian Pacific Association for the Study of the Liver (APASL)—emphasize individualized, risk-stratified management rather than rigid numerical cutoffs.